Drug firm Divi’s Laboratories’ consolidated net profit rose by 23.81% to Rs 216.91 crore for the fourth quarter ended December 31, 2012, on account of robust sales during the quarter. The company had posted a net profit of Rs 175.19 crore during the same period of previous fiscal.
The company’s net sales rose by 47.50% to Rs 722.53 crore for the fourth quarter, as compared to Rs 489.82 crore during the same period previous financial year.
For the year ended March 31, 2012, the company reported a jump of 24.23% in its net profit of Rs 533.26 crore as against Rs 429.27 crore during 2010-11.
The company’s net sales for the year ended March 31, 2012 rose to Rs 1920.01 crore, compared to Rs 1343.66 crore during 2010-11, up by 42.89%.
The company’s board recommended a dividend of Rs 13 per share of Rs 2 each for the year ended March 31, 2012.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: